Recombinant Human COMT Protein

重组人COMT蛋白 | 重组人儿茶酚-O-甲基转移酶蛋白

catechol O-methyltransferase | catechol-O-methyltransferase | COMT | EC 2.1.1.6

rp184883-10μg

10μg

无载体

≥95%(SDS-PAGE)

Catechol-O-methyltransferase (COMT) catalyzes the transfer of the methyl group from S-adenosyl-L-methionine to either the meta- or the para-hydroxyl group of the catechol ring from a variety of endogenous and exogenous catechol substrates including the neurotransmitters dopamine, epinephrine, and norepinephrine. Thus, it plays important roles in one of the major degradative pathways of the catecholamine transmitters, and in the metabolism of catechol drugs used in the treatment of hypertension, asthma, and Parkinson’s disease. In tissues, COMT is produced as two distinct forms, a soluble protein (residues 52-271) and a membrane-bound protein that possesses the N-terminal transmembrane domain. A common single-nucleotide polymorphism results in substitution of methionine for valine at position 158 of membrane-bound COMT and position 108 at soluble COMT. This amino acid change results in a more unstable and three- to four-fold less active 108/158Met form. Since COMT activity is the major regulator of dopamine function in the prefrontal brain region, the Val108/158Met variation is considered to be associated with increased risk of a wide spectrum of mental disorders. Post-translational: The N-terminus is blocked.

Immobilized Recombinant Human COMT Protein (rp184883) at 1.0 μg/mL can bind COMT Antibody (Ab097283) with the EC50 of 5.6 ng/mL.

重组表达

25.3 kDa

C-His

24.4 kDa, under reducing conditions; 24.4 kDa, under non-reducing conditions.

E. coli Accession #: P21964 | E. coli

<1.0 EU/μg

人(Human)

52-271 aa

MGDTKEQRILNHVLQHAEPGNAQSVLEAIDTYCEQKEWAMNVGDKKGKIVDAVIQEHQPSVLLELGAYCGYSAVRMARLLSPGARLITIEINPDCAAITQRMVDFAGVKDKVTLVVGASQDIIPQLKKKYDVDTLDMVFLDHWKDRYLPDTLLLEECGLLRKGTVLLADNVICPGAPDFLAHVRGSSCFECTHYQSFLEYREVVDGLEKAIYKGPGSEAGPHHHHHH

No

Yes